Attovia Therapeutics (ATTO) Q3 2026 earnings summary

Executive summary

• Positive 12-week Phase 1b results for ATTO-1310 showed sustained itch relief and skin improvements in chronic pruritus and high-itch atopic dermatitis.

• Q3 R&D investment accelerated across the pipeline; the August IPO strengthened liquidity as operating and net losses widened YoY.

• ATTO-1310 Phase 2 trials and Phase 1 trials for ATTO-2306 and ATTO-1091 are planned for 1H 2027.

Financial highlights

• Q3 2026 collaboration revenue was $0, versus $0.4M in Q3 2025; 9M revenue was $0.45M versus $0.36M.

• Q3 R&D expense rose 65% to $20.29M and G&A rose 30% to $4.73M; total operating expenses increased 57% to $25.02M.

• Q3 operating loss was $25.02M versus $15.60M; net loss was $22.27M versus $13.78M.

• 9M 2026 R&D was $55.98M versus $37.76M; net loss was $61.61M versus $43.37M.

Outlook and guidance

• Cash, cash equivalents and marketable securities of $395.9M at September 30, 2026 are expected to fund operations into 2030, subject to assumptions and change.

• ATTUNE Phase 2 trials in CPUO and high-itch AD, and Phase 1 trials for ATTO-2306 and ATTO-1091, are planned for 1H 2027; ATTO-1091 timing is subject to IND clearance.

• ATTO-1310 cholestatic pruritus Phase 1b topline results from China are expected in 2H 2027.

• R&D and G&A expenses are expected to increase as clinical programs advance, the pipeline expands, and public-company and potential commercialization capabilities grow.